RADNOR,
Pa., April 27, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, a Delaware
Corporation, today announced that it will release its first quarter
2023 financial results after the market closes on Thursday, May 11, 2023, via press release, which
will be available on the Company's website at
https://ir.nrxpharma.com/. The Company will host a conference call
to discuss the financial results as well as provide a corporate
update at 4:30 p.m. ET the same
day.
NRx Pharmaceuticals to Report First Quarter
2023 Financial Results on May 11,
2023
A live webcast of the conference call will be available on the
Company's website
at https://ir.nrxpharma.com/news-events/ir-calendar. An
archive of the webcast will be available on the Company's website
for 30 days.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically +1 (833)
630-1956 or internationally +1 (412) 317-1837.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics for the treatment of central
nervous system disorders, specifically bipolar depression with
suicidality and post-traumatic stress disorder (PTSD). The
company's lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's
N-methyl-D-aspartate (NMDA) receptor and is being investigated in a
Phase 2b/3 clinical trial for
suicidal treatment-resistant bipolar depression, which includes
patients with both acute and sub-acute suicidality, an indication
for which the only approved treatment is electroshock therapy. The
company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101
in patients with Severe Bipolar Depression with Acute Suicidal
Ideation & Behavior (ASIB) demonstrated a substantial
improvement over available therapy in reducing depression and
suicidality compared to placebo when patients were treated with
NRX-101 after a single dose of ketamine. Based on the findings from
the STABIL-B trial, the U.S. Food and Drug Administration (FDA)
granted a Special Protocol Agreement and Breakthrough Therapy
Designation for NRX-101 in patients with Severe Bipolar Depression
with ASIB.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-11-2023-301810120.html
SOURCE NRx Pharmaceuticals, Inc.